Login to Your Account



Corgentech Files For $86M IPO, Pins Hopes On Vein-Graft Drug

By Randall Osborne


Monday, December 8, 2003
On the heels of a major deal with Bristol-Myers Squibb Co. to develop its treatment called E2F Decoy for preventing post-surgery vein-graft failure, Corgentech Inc. has registered an initial public offering to raise $86.25 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription